More Life Company Corp. (MLCO.CN)
Full history for every metric is available with a Kvantra account
No price history available.
Key financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Total revenue | CAD m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | CAD m | -2 | -2 | ||||||
| Net profit | CAD m | -19 | -8 | -10 | -7 | -8 | -7 | -3 | -3 |
| EPS reported | CAD | -0.01 | -0.01 | ||||||
| Operating cashflow per share | CAD | -0.01 | -0.01 | ||||||
| Capex per share | CAD | 0.00 | 0.00 | ||||||
| FCF per share | CAD | -0.01 | -0.01 | ||||||
| Free cash flow | CAD m | -2 | -1 | ||||||
| Net debt | CAD m | 0 | 0 | ||||||
| Book value equity | CAD m | -0 | -0 | ||||||
| Book value per share | CAD | -0.00 | -0.00 | ||||||
| Number of shares | m | 352.35 | 352.35 | ||||||
| DPS (TTM paid) | CAD | - | 0.00 |
Financial summary
Financials in CAD| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | TTM | ||
|---|---|---|---|---|---|---|---|---|---|
| Value | |||||||||
| P/E TTM | x | - | - | ||||||
| P/B LTM | x | -199.92 | -61.78 | ||||||
| P/S LTM | x | 433.67 | 134.01 | ||||||
| P/FCF LTM | x | -13.33 | -6.27 | ||||||
| EV/EBITDA LTM | x | -12.48 | -3.09 | ||||||
| EV/Sales LTM | x | 435.11 | 493.60 | ||||||
| Earnings Yield LTM | % | -9.92% | -11.33% | ||||||
| FCF Yield | % | -7.50% | -15.95% | ||||||
| Quality | |||||||||
| ROE | % | - | -314.49% | ||||||
| ROIC | % | -8.91% | -8.91% | ||||||
| Operating margin | % | -35.91% | -35.91% | ||||||
| Gross margin | % | -3.08% | +56.92% | ||||||
| FCF/Sales | % | -3253.85% | -3098.46% | ||||||
| Growth and momentum | |||||||||
| EPS Growth YoY | % | - | - | ||||||
| Sales Growth YoY | % | +32.65% | +8.33% | ||||||
| Net Income Growth YoY | % | - | - | ||||||
| FCF Growth | % | - | - | ||||||
| Operating Profit Growth | % | - | - | ||||||
| Dividend and capital structure | |||||||||
| Dividend Yield | % | 0.00% | 0.00% | ||||||
| Dividend Growth | % | - | - | ||||||
| Payout Ratio | % | - | 0.00% | ||||||
| FCF/Debt | x | -5.25 | -3.45 | ||||||
| Net Debt/EBITDA | x | -0.04 | -0.04 | ||||||
| EBIT/Net interest | x | 0.00 | 0.00 | ||||||
| Net debt/market cap | % | +1.43% | +1.26% | ||||||
| Net debt/Equity | x | -0.49 | -0.49 | ||||||
| Gross debt/equity | x | -2.86 | -2.86 | ||||||
Ratings
Based on consensus from external analysts. Not Kvantra's opinion.
Company overview
The More Life Co. Corp. is a biotechnology company, which engages in the provision of solutions to optimize human, animal, and plant health. Its patented technologies includes Quicksome™ and Quicksol™. The Quicksome™ patented technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into product formats that, if successfully commercialized, could enhance the efficacy of molecule delivery across a variety of nutraceutical product applications. The Quicksol™ patented is a solubilization technology, which has been developed to provide solubilized drug delivery options. The company was founded on March 8, 2005 and is headquartered in Vaughan, Canada.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
No price history available.
Not enough data to calculate KvantraRank
Based on consensus from external analysts. Not Kvantra's opinion.
The More Life Co. Corp. is a biotechnology company, which engages in the provision of solutions to optimize human, animal, and plant health. Its patented technologies includes Quicksome™ and Quicksol™. The Quicksome™ patented technology utilizes proprietary formulations and stabilizing molecules to encapsulate and formulate active ingredients into product formats that, if successfully commercialized, could enhance the efficacy of molecule delivery across a variety of nutraceutical product applications. The Quicksol™ patented is a solubilization technology, which has been developed to provide solubilized drug delivery options. The company was founded on March 8, 2005 and is headquartered in Vaughan, Canada.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free